Retatrutide: Complete Research Review of the Triple Receptor Agonist (LY3437943)
Shop Our Top Compounds
Retatrutide Triple Receptor Agonist: Complete Research Review (LY3437943)
Retatrutide: Complete Research Review of the Triple Receptor Agonist (LY3437943)
All information presented in this article is for research purposes only. Retatrutide (LY3437943) is an investigational compound not approved for human use. Not for human consumption.
Introduction: A New Frontier in Multi-Receptor Agonist Research
The metabolic research landscape has undergone a seismic shift in recent years. From single-target GLP-1 receptor agonists to dual GIP/GLP-1 agonists, each successive generation of incretin-based molecules has delivered progressively greater efficacy in preclinical and clinical models. Now, retatrutide (LY3437943) — Eli Lilly’s investigational triple receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously — represents the most advanced triple agonist in clinical development and may define the next chapter of metabolic research.
Eli Lilly, a medicine company turning science into therapeutic solutions, has a long history of pioneering life changing discoveries that have transformed healthcare. As a leading medicine company, Lilly’s innovative medicines reach tens of millions of people worldwide, underscoring their global impact. Their commitment to redefining diabetes care is evident in the ongoing drug research and development of novel therapies like retatrutide.
What makes retatrutide particularly significant for the research community is not only the magnitude of body weight reduction observed in clinical trials — up to 24.2% in 48 weeks and 28.7% at 68 weeks — but also its broad metabolic impact across glycemic control, hepatic fat reduction, lipid parameters, and cardiovascular risk markers. Published data from phase 1, phase 2, and now emerging phase 3 trials have established retatrutide as one of the most closely watched investigational molecules in metabolic science.
This research review examines the published evidence for retatrutide across its mechanism of action, clinical trial data, metabolic effects, pharmacokinetics, safety profile, and ongoing phase 3 program. For researchers seeking to understand the current state of triple receptor agonist science, this guide consolidates the key findings from peer-reviewed literature and clinical trial registries. For further context on peptide research terminology, see the Peptide Glossary.
The Triple Agonism Mechanism: GIP, GLP-1, and Glucagon Receptor Activation
Understanding Multi-Receptor Pharmacology
Retatrutide is a single synthetic peptide engineered to simultaneously activate three distinct G protein-coupled receptors (GPCRs): the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple agonism approach is designed to harness the complementary metabolic pathways governed by each receptor system, producing effects that exceed what any single- or dual-receptor agonist can achieve alone.
In vitro characterization has demonstrated that retatrutide exhibits balanced activity at the GLP-1 and glucagon receptors with comparatively greater activity at the GIP receptor (Coskun et al., 2022). This receptor activity profile was intentionally optimized during the molecule’s design to maximize synergistic metabolic effects while maintaining an acceptable tolerability profile.
The Role of Each Receptor
GLP-1 Receptor Activation: GLP-1R agonism drives appetite suppression through central nervous system signaling, enhances glucose-dependent insulin secretion from pancreatic beta cells, and slows gastric emptying. These are well-established mechanisms validated through decades of research on GLP-1 receptor agonists like semaglutide and liraglutide.
GIP Receptor Activation: The GIP receptor plays a complementary role in glucose homeostasis and energy balance. Research has demonstrated that GIP receptor agonism potentiates the insulinotropic effects of GLP-1 signaling, enhances lipid metabolism, and may improve adipose tissue function. The dual GIP/GLP-1 agonist tirzepatide validated this approach in multiple phase 3 clinical trials, demonstrating that adding GIP receptor activation to GLP-1 signaling amplifies metabolic benefits.
Glucagon Receptor Activation: The addition of glucagon receptor agonism is what distinguishes retatrutide from all currently available or approved incretin-based therapeutics. Glucagon receptor activation stimulates hepatic energy expenditure, promotes lipid oxidation, increases thermogenesis, and mobilizes hepatic fat stores. In preclinical models, researchers observed that GCGR-mediated increases in energy expenditure, combined with GIPR- and GLP-1R-driven calorie intake reduction, produced weight loss significantly greater than either mechanism alone (Coskun et al., 2022).
Synergistic Effects in Preclinical Models
In diet-induced obese (DIO) mouse models, administration of retatrutide produced dose-dependent reductions in body weight and improvements in glycemic control that exceeded the effects of matched GLP-1R-only or GIP/GLP-1R dual agonist comparators. The preclinical data confirmed that the glucagon receptor component adds a critical energy expenditure dimension to the appetite suppression and insulinotropic effects of GIP/GLP-1 agonism, creating a multi-mechanism approach to metabolic intervention (Coskun et al., 2022).
Retatrutide vs. Dual and Mono Agonists: How Triple Agonism Compares
The Evolutionary Trajectory of Incretin Research
Understanding retatrutide’s position in the incretin agonist research landscape requires context on its predecessors:
Semaglutide (mono GLP-1R agonist): The STEP trials demonstrated approximately 15–17% body weight reduction at 68 weeks in participants with obesity (Wilding et al., 2021). Semaglutide remains the benchmark single-receptor agonist in published literature.
Tirzepatide (dual GIP/GLP-1R agonist): The SURMOUNT-1 trial demonstrated up to 22.5% body weight reduction at 72 weeks, establishing that adding GIP receptor activation to GLP-1 signaling produces meaningfully greater weight reduction than GLP-1 alone (Jastreboff et al., 2022).
Retatrutide (triple GIP/GLP-1R/GCGR agonist): Phase 2 data demonstrated up to 24.2% body weight reduction at just 48 weeks — with weight loss curves still declining and not yet reaching a plateau (Jastreboff et al., 2023). Phase 3 TRIUMPH-4 data subsequently demonstrated 28.7% weight loss at 68 weeks (Eli Lilly, 2025).
Why the Glucagon Component Matters
The critical differentiator for retatrutide is the glucagon receptor agonism. While GLP-1 and GIP receptor activation primarily reduce caloric intake through appetite regulation, delayed gastric emptying, and improved satiety signaling, glucagon receptor activation works on the other side of the energy balance equation by increasing energy expenditure. Research has shown that glucagon promotes hepatic fatty acid oxidation, increases resting metabolic rate, and mobilizes fat from hepatic stores — mechanisms that are particularly relevant for addressing fatty liver disease and maintaining metabolic rate during weight loss. In contrast, glucagon receptor antagonists have been associated with increased hepatic fat, whereas glucagon receptor agonists like retatrutide can lead to substantial reductions in liver fat content and improvements in metabolic health.
This dual-sided approach — reducing energy intake and increasing energy expenditure — may explain why retatrutide has produced unprecedented weight reduction in clinical trials while simultaneously showing exceptional hepatic fat clearance, a benefit not as robustly observed with GLP-1-only or GIP/GLP-1 dual agonists. The development of triple agonists like retatrutide represents a significant advancement in genetic medicine, leveraging biotechnology to address complex metabolic diseases.
Phase 2 Clinical Trial Data: The Landmark Obesity Study
Study Design and Population
The pivotal phase 2 trial of retatrutide in obesity (NCT04881760) was a double-blind, randomized, placebo-controlled study published in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with a BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity. Notably, 51.8% of participants were men — a higher proportion than most obesity trials — providing valuable data on retatrutide’s effects across sexes.
Participants were randomly assigned to receive once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg (with various dose escalation protocols) or placebo for 48 weeks. The primary endpoint was percentage change in body weight from baseline to 24 weeks (Jastreboff et al., 2023).
Weight Reduction Results
The results demonstrated significant weight loss and established retatrutide as a safe and effective treatment in the field of pharmacological obesity research:
At 24 weeks (primary endpoint):
Placebo: −1.6%
Retatrutide 1 mg: −7.2%
Retatrutide 4 mg (combined): −12.9%
Retatrutide 8 mg (combined): −17.3%
Retatrutide 12 mg: −17.5%
At 48 weeks (secondary endpoint):
Placebo: −2.1%
Retatrutide 1 mg: −8.7%
Retatrutide 4 mg (combined): −17.1%
Retatrutide 8 mg (combined): −22.8%
Retatrutide 12 mg: −24.2%
Critically, the weight loss trajectories at 48 weeks had not yet plateaued in the higher dose groups, suggesting that longer treatment duration could yield even greater reductions — a hypothesis that the phase 3 program is now testing.
Categorical Weight Loss Thresholds
At the 12 mg dose at 48 weeks:
100% of participants achieved ≥5% body weight reduction
93% achieved ≥10% body weight reduction
83% achieved ≥15% body weight reduction
These categorical outcomes are particularly notable because ≥15% weight loss is associated with resolution or significant improvement in multiple obesity-related comorbidities in published research (Jastreboff et al., 2023).
Phase 3 Program Update: The TRIUMPH and TRANSCEND Trials
Current Trial Portfolio
Eli Lilly’s phase 3 program for retatrutide encompasses multiple large-scale trials under the TRIUMPH and TRANSCEND banners:
TRIUMPH-1: Evaluating retatrutide in adults with obesity (NCT05929066)
TRIUMPH-3: Evaluating retatrutide for obesity with cardiovascular outcomes (NCT06383390)
TRIUMPH-4: Evaluating retatrutide in adults with obesity and knee osteoarthritis — completed with positive topline results (NCT05882045)
TRIUMPH-6: Evaluating weight maintenance with retatrutide (NCT06859268)
TRANSCEND-T2D-1: Evaluating retatrutide in type 2 diabetes — completed with positive topline results (NCT05929079)
TRIUMPH-4 Phase 3 Results (December 2025)
The first phase 3 data readout came from TRIUMPH-4, which studied retatrutide in adults with obesity and moderate-to-severe knee osteoarthritis. At 68 weeks, participants receiving retatrutide 12 mg achieved an average body weight reduction of 28.7% (approximately 71.2 lbs), with co-primary endpoint of 75.8% reduction in knee osteoarthritis pain scores. These results exceeded phase 2 projections and demonstrated that weight loss had not yet fully plateaued at 68 weeks (Eli Lilly, 2025).
TRANSCEND-T2D-1 Phase 3 Results (March 2026)
The TRANSCEND-T2D-1 trial evaluated retatrutide in 537 adults with type 2 diabetes. Retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks and produced weight loss of up to 16.8% — with weight loss curves still declining. No weight-loss plateau was observed across the treatment period (Eli Lilly, 2026).
Body Composition Research: Fat Mass vs. Lean Mass
The Importance of Body Composition Analysis
A key concern in pharmacological weight loss research is the ratio of fat mass to lean mass loss. Excessive lean mass reduction during weight loss can impair metabolic rate, physical function, and long-term outcomes. Research into retatrutide’s effects on body composition has been an active area of investigation.
Published Body Composition Data
A substudy of the phase 2 type 2 diabetes trial evaluated body composition using dual-energy X-ray absorptiometry (DXA) in participants receiving retatrutide. Published in The Lancet Diabetes & Endocrinology in 2025, the data demonstrated that retatrutide significantly improved body composition with greater fat mass reduction compared to lean mass loss. Fat mass measured by DXA decreased substantially across all dose groups compared with placebo and the active comparator dulaglutide (Coskun et al., 2025).
The glucagon receptor component of retatrutide is hypothesized to play a role in fat-preferential weight loss through its stimulation of hepatic fatty acid oxidation and thermogenesis. Glucagon receptor activation has been shown in preclinical models to preferentially mobilize lipid stores and increase resting energy expenditure — both mechanisms that theoretically favor fat-over-lean mass loss. However, the precise contribution of each receptor component to body composition changes remains an active area of investigation.
Visceral and Subcutaneous Adipose Tissue
Data from the MASLD substudy (Sanyal et al., 2024) included MRI-based assessments of both visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (SAT). Retatrutide produced statistically significant, dose-dependent reductions in both VAT and SAT volumes compared with placebo. Since visceral adiposity is more strongly correlated with cardiometabolic risk than subcutaneous fat, these findings have important implications for the broader metabolic impact of retatrutide-mediated weight loss. Researchers interested in the relationship between peptide research and body composition will find this area of investigation particularly relevant.
Glycemic Control Research: A1C Reduction and Glucose Homeostasis
Phase 2 Data in Type 2 Diabetes
The phase 2 trial in people with type 2 diabetes (NCT04867785) provided robust glycemic efficacy data. Published in The Lancet in 2023, the study enrolled 281 participants and evaluated retatrutide across multiple dose groups compared to placebo and active comparator dulaglutide 1.5 mg (Rosenstock et al., 2023).
HbA1c reductions at 24 weeks:
Placebo: −0.01%
Dulaglutide 1.5 mg: −1.41%
Retatrutide 0.5 mg: −0.43%
Retatrutide 4 mg: −1.30% to −1.39%
Retatrutide 8 mg: −1.88% to −1.99%
Retatrutide 12 mg: −2.02%
HbA1c reductions with retatrutide at the 8 mg and 12 mg doses were statistically significantly greater than both placebo and the active comparator dulaglutide (p<0.01 and p<0.001, respectively). Results were consistent at 36 weeks.
Body weight reductions at 36 weeks in the T2D population:
Retatrutide 8 mg: −16.3% to −16.8%
Retatrutide 12 mg: −16.9%
Importantly, no episodes of severe hypoglycemia were reported during the study, and glucose-lowering appeared to be glucose-dependent — consistent with the mechanism of incretin-based therapies (Rosenstock et al., 2023).
Phase 1b Glycemic Data
Earlier phase 1b data (NCT04143802) had demonstrated proof of concept, with placebo-adjusted reductions in mean daily plasma glucose of up to 3.1 mmol/L and HbA1c reductions of up to 1.6% (placebo-adjusted) at the highest dose groups after just 12 weeks of treatment (Urva et al., 2022).
Hepatic Effects: Liver Fat Reduction and MASLD/NASH Implications
The MASLD Substudy
One of the most striking findings from the retatrutide phase 2 program was the magnitude of liver fat reduction observed in a prespecified substudy of participants with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Published in Nature Medicine in 2024, this substudy evaluated 98 participants with ≥10% liver fat content measured by MRI-proton density fat fraction (MRI-PDFF) (Sanyal et al., 2024).
Liver Fat Reduction Results
Mean relative change in liver fat at 24 weeks:
Placebo: +0.3%
Retatrutide 1 mg: −42.9%
Retatrutide 4 mg: −57.0%
Retatrutide 8 mg: −81.4%
Retatrutide 12 mg: −82.4%
All retatrutide doses produced statistically significant liver fat reductions compared to placebo (all p<0.001).
Normalization of Liver Fat Content
Percentage of participants achieving normal liver fat (<5%) at 24 weeks:
Placebo: 0%
Retatrutide 1 mg: 27%
Retatrutide 4 mg: 52%
Retatrutide 8 mg: 79%
Retatrutide 12 mg: 86%
At the 8 mg and 12 mg doses, greater than 85% of participants achieved complete normalization of liver fat content — a result that is unprecedented in pharmacological MASLD research. The study also demonstrated significant reductions in biomarkers of hepatic inflammation and fibrogenesis, including keratin-18 (K-18) and pro-C3, suggesting potential benefits beyond simple fat clearance (Sanyal et al., 2024).
Mechanistic Considerations
The remarkable hepatic effects of retatrutide are likely driven primarily by the glucagon receptor component. Glucagon is a key regulator of hepatic lipid metabolism, promoting fatty acid oxidation and reducing hepatic lipogenesis. The combination of GCGR-mediated hepatic fat mobilization with GLP-1R/GIPR-driven improvements in insulin sensitivity and overall weight reduction creates a multi-pronged approach to liver fat clearance that neither GLP-1 agonists nor GIP/GLP-1 dual agonists have replicated to the same degree.
Cardiovascular Parameters: Blood Pressure, Lipids, and Risk Markers
Cardiometabolic Improvements in Clinical Trials
Across the phase 2 clinical program, retatrutide treatment was associated with dose-dependent improvements in multiple cardiovascular risk parameters. Published analyses have documented significant improvements in the following markers:
Lipid Parameters:
Triglycerides: Reductions of up to approximately 40.6% at the 12 mg dose at 48 weeks
Apolipoprotein C-III (apoC-III): Reductions of up to 38%
Non-HDL cholesterol: Significant reductions across dose groups
Total lipoprotein particle number: Meaningful reductions at higher doses
Blood Pressure:
Systolic blood pressure reductions were observed in a dose-dependent manner across retatrutide groups
Diastolic blood pressure also declined, consistent with weight-mediated and potentially direct vascular effects
Waist Circumference:
Reductions paralleled body weight changes, with clinically meaningful decreases reflecting visceral adipose tissue loss
These cardiometabolic improvements prompted Eli Lilly to initiate a dedicated cardiovascular outcomes trial (TRIUMPH-3, NCT06383390), which is currently enrolling participants with obesity and established cardiovascular disease to evaluate whether retatrutide reduces major adverse cardiovascular events (MACE).
Heart Rate Considerations
Research has noted dose-dependent increases in heart rate that peaked at approximately 24 weeks and subsequently declined through week 48. This pattern is consistent with GLP-1 receptor agonist class effects and was not associated with adverse cardiovascular outcomes in the phase 2 program (Jastreboff et al., 2023).
Pharmacokinetics: Half-Life, Dosing, and Administration
Pharmacokinetic Profile
The pharmacokinetic properties of retatrutide have been characterized across phase 1 and phase 2 clinical studies:
Half-life: Approximately 6 days (range reported as 5–7 days across studies), supporting once-weekly subcutaneous administration
Dose proportionality: Pharmacokinetics are dose-proportional across the studied dose range
Steady state: Achieved within approximately 4–5 weeks of once-weekly dosing
Route: Subcutaneous injection
Dosing frequency: Once weekly; participants are titrated to a target dose over several weeks during dose escalation in clinical trials.
Phase 1 Single Ascending Dose Data
The phase 1 single ascending dose (SAD) study was conducted in 47 healthy volunteers in Singapore (NCT03841630). Researchers administered single subcutaneous doses of retatrutide ranging from 0.1 mg to 6 mg. The study demonstrated a safety and tolerability profile similar to other incretin-based peptides, with pharmacokinetics supporting once-weekly dosing. Notably, a reduction in body weight was observed that persisted up to day 43 following a single dose, providing early evidence of sustained pharmacological activity (Coskun et al., 2022).
Phase 1b Multiple Ascending Dose Data
The phase 1b multiple ascending dose (MAD) study (NCT04143802) in 72 adults with type 2 diabetes further confirmed dose-proportional pharmacokinetics with a half-life of approximately 6 days. Five ascending dose cohorts were studied over 12 weeks, with the two highest dose cohorts employing stepwise dose escalation protocols designed to reach a target dose for efficacy and safety evaluation. These protocols informed the titration strategies used in subsequent phase 2 and phase 3 trials (Urva et al., 2022).
Safety and Tolerability Data From Clinical Trials
Gastrointestinal Adverse Events
Consistent with the broader incretin agonist class, the most commonly reported adverse effects in retatrutide clinical trials have been gastrointestinal in nature. In the phase 2 obesity trial, gastrointestinal adverse events were dose-related, generally mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg versus 4 mg initial dose) (Jastreboff et al., 2023). These adverse effects included decreased appetite as a common event.
Commonly reported GI adverse events across the phase 2 program:
Nausea (most common, dose-dependent, typically transient)
Diarrhea
Vomiting
Constipation
Decreased appetite
The most common adverse events reported among participants treated with retatrutide were nausea (38.1% and 43.2% for 9 mg and 12 mg doses, respectively), diarrhea (34.7% and 33.1%), constipation (21.8% and 25.0%), vomiting (20.4% and 20.9%), and decreased appetite (19.0% and 18.2%), compared to lower rates in the placebo group. These gastrointestinal events were generally mild to moderate and mostly resolved during treatment.
In a substudy of participants with metabolic dysfunction-associated steatotic liver disease (MASLD), transient and generally mild-to-moderate gastrointestinal events were the most frequently reported adverse events, with higher frequencies observed in the 8 mg and 12 mg dose groups.
In the phase 2 type 2 diabetes trial, GI adverse events occurred in 35% of retatrutide-treated participants across all dose groups combined (ranging from 13% at 0.5 mg to 50% at 8 mg fast-escalation), compared to 13% in the placebo group and 35% in the dulaglutide 1.5 mg group (Rosenstock et al., 2023).
Serious Adverse Events and Discontinuations
Serious adverse events were infrequent across the phase 2 program. No deaths were reported during either the obesity or type 2 diabetes phase 2 trials. There were no reports of severe hypoglycemia in the type 2 diabetes study. Treatment discontinuations due to adverse events were primarily related to GI tolerability and were more frequent at higher doses, particularly with faster dose escalation (Jastreboff et al., 2023; Rosenstock et al., 2023).
Phase 3 Safety Signals
In the TRIUMPH-4 phase 3 trial, the overall safety profile was consistent with the phase 2 data, supporting retatrutide as a safe and effective treatment in clinical trials. Gastrointestinal events remained the most common adverse events. The TRANSCEND-T2D-1 trial in type 2 diabetes also confirmed a safety profile consistent with prior studies, with no new safety signals emerging at 40 weeks.
Dose Escalation Strategy
An important clinical finding from the phase 2 program was that a slower dose escalation starting at 2 mg (rather than 4 mg) significantly reduced the incidence and severity of GI adverse events at the beginning of treatment. This observation directly informed the titration strategy adopted in the phase 3 program, where all participants begin at 2 mg with stepwise escalation over several weeks to the target maintenance dose.
Frequently Asked Questions About Retatrutide Research
What is retatrutide (LY3437943)?
Retatrutide (LY3437943) is an investigational single-peptide molecule developed by Eli Lilly that simultaneously activates three metabolic receptors: the GIP receptor, GLP-1 receptor, and glucagon receptor. It is the most clinically advanced triple receptor agonist in development and has demonstrated unprecedented body weight reduction and metabolic improvements in clinical trials. Information about retatrutide is based on data from press releases, published studies, and systematic reviews. Retatrutide and other Lilly medicines are also being studied for their potential in treating difficult to treat cancers, chronic low back pain, and debilitating immune system disorders. Retatrutide is currently in phase 3 clinical trials and is not approved for human use. All retatrutide research compounds are for research purposes only.
How does retatrutide differ from tirzepatide and semaglutide?
Semaglutide is a single GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide adds a third receptor — the glucagon receptor — to the GIP/GLP-1 combination. In published clinical trials, this triple agonist approach has produced the largest magnitude of body weight reduction observed in pharmacological obesity research, directly addressing weight gain associated with obesity and metabolic disorders. The glucagon receptor component is thought to contribute additional benefits through increased energy expenditure and enhanced hepatic fat clearance, effects not directly mediated by GLP-1 or GIP receptor activation alone. According to systematic review evidence, incretin-based therapies like retatrutide are effective in improving metabolic outcomes and reducing weight gain, supporting their use in comprehensive obesity and diabetes management.
What were the key results from the retatrutide phase 2 obesity trial?
The phase 2 obesity trial (published in the New England Journal of Medicine, 2023) demonstrated that retatrutide initiated treatment at the 12 mg dose produced a mean body weight reduction of 24.2% at 48 weeks, with 100% of participants achieving ≥5% weight loss and 83% achieving ≥15% weight loss. Weight loss trajectories had not yet plateaued, and the subsequent TRIUMPH-4 phase 3 trial demonstrated 28.7% weight loss at 68 weeks.
What liver fat reduction has been observed in retatrutide research?
A prespecified substudy published in Nature Medicine (2024) demonstrated that retatrutide at 8 mg and 12 mg reduced liver fat content by over 80% from baseline at 24 weeks. At the 12 mg dose, 86% of participants achieved complete normalization of liver fat (<5%) at 24 weeks. These are the most robust liver fat reduction results reported for any incretin-based therapy in published literature.
What is the current status of retatrutide clinical trials?
As of early 2026, retatrutide is in phase 3 clinical development with multiple active trials under the TRIUMPH (obesity) and TRANSCEND (type 2 diabetes) programs. TRIUMPH-4 and TRANSCEND-T2D-1 have reported positive topline results. Additional trials evaluating obesity (TRIUMPH-1), cardiovascular outcomes (TRIUMPH-3), and weight maintenance (TRIUMPH-6) are ongoing. Eligibility for these trials often considers medical history, including conditions such as gallbladder disease, to ensure patient safety. Eli Lilly has not announced a specific timeline for regulatory submission. The information provided reflects Lilly’s current beliefs about retatrutide’s potential, but drug development and regulatory approval involve substantial risks and other risks, and outcomes may differ from expectations.
What is the half-life and dosing schedule of retatrutide?
Retatrutide has a pharmacokinetic half-life of approximately 6 days, which supports once-weekly subcutaneous dosing. In clinical trials, researchers administered doses ranging from 1 mg to 12 mg once weekly, with stepwise dose escalation from a 2 mg starting dose to reduce gastrointestinal adverse events during the titration period.
Conclusion: Retatrutide and the Future of Triple Agonist Research
Retatrutide represents a paradigm-shifting advance in multi-receptor agonist research. The published evidence — spanning preclinical characterization, phase 1 pharmacokinetic studies, phase 2 efficacy trials, and now emerging phase 3 data — consistently demonstrates that simultaneous activation of the GIP, GLP-1, and glucagon receptors produces metabolic effects that exceed those of any single- or dual-receptor agonist studied to date.
The key findings from published retatrutide research include:
Body weight reduction of up to 24.2% at 48 weeks (phase 2) and 28.7% at 68 weeks (phase 3)
HbA1c reduction of up to 2.0% in people with type 2 diabetes
Liver fat normalization in over 85% of participants with MASLD at higher doses
Broad cardiometabolic improvements in lipids, blood pressure, and inflammatory markers
A manageable safety profile consistent with the incretin agonist class
For researchers studying the intersection of incretin biology, energy metabolism, and hepatic lipid regulation, retatrutide offers a uniquely informative pharmacological tool. The compound’s ability to simultaneously address appetite, energy expenditure, glycemic dysregulation, and hepatic steatosis through a single molecule underscores the therapeutic potential of multi-receptor agonism. The ongoing phase 3 program — including dedicated cardiovascular outcomes, weight maintenance, and sleep apnea studies — will provide additional long-term efficacy, safety, and outcomes data that will further define the role of triple agonism in metabolic research.
As the science of incretin-based peptide research continues to evolve, retatrutide stands as the leading edge of a new class of multi-receptor agonists that may fundamentally reshape how researchers approach metabolic disease. Explore our full range of research peptides and metabolic compounds at Iron Peak Peptides.
Explore Iron Peak Peptides’ full catalog of research-grade compounds to support your metabolic research programs. Shop our research peptide collection and discover our commitment to purity, quality, and scientific rigor. For a comprehensive overview of incretin-based peptide research, visit our BPC-157 Complete Guide and the Peptide Glossary.
References
Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 389(6), 514–526, 2023. DOI: 10.1056/NEJMoa2301972
Rosenstock J, Frias JP, Jastreboff AM, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” The Lancet, 402(10401), 529–544, 2023. DOI: 10.1016/S0140-6736(23)01053-X
Coskun T, Urva S, Roell WC, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metabolism, 34(9), 1234–1247, 2022. DOI: 10.1016/j.cmet.2022.07.013
Urva S, Coskun T, Loh MT, et al. “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.” The Lancet, 400(10366), 1869–1881, 2022. DOI: 10.1016/S0140-6736(22)02033-5
Sanyal AJ, Kaplan LM, Frias JP, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature Medicine, 30(7), 2037–2048, 2024. DOI: 10.1038/s41591-024-03018-2
Coskun T, Wu Q, Schloot NC, et al. “Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.” The Lancet Diabetes & Endocrinology, 13(8), 674–684, 2025. DOI: 10.1016/S2213-8587(25)00092-0
Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 384(11), 989–1002, 2021. DOI: 10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 387(4), 327–340, 2022. DOI: 10.1056/NEJMoa2206038
Patti ME. “Triple G Agonists — A Home Run for Obesity?” New England Journal of Medicine, 389(6), 562–563, 2023. DOI: 10.1056/NEJMe2307282
Müller TD, Tschöp MH. “Gut-hormone triple agonists: clinical safety and metabolic benefits.” The Lancet, 400(10366), 1826–1828, 2022. DOI: 10.1016/S0140-6736(22)02350-9
Bain SC, Min T. “A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.” The Lancet, 402(10401), 504–505, 2023. DOI: 10.1016/S0140-6736(23)01182-0
Katsi V, Koutsopoulos G, Fragoulis C, et al. “Retatrutide—A Game Changer in Obesity Pharmacotherapy.” Biomolecules, 15(6), 796, 2025. DOI: 10.3390/biom15060796
Kaur M, Misra S. “A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.” European Journal of Clinical Pharmacology, 80(5), 669–676, 2024. DOI: 10.1007/s00228-024-03646-0
Elfeki MA, Alkhouri N. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine, 389(17), 1629, 2023. DOI: 10.1056/NEJMc2310645
Eli Lilly and Company. “Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful phase 3 trial.” Press release, December 11, 2025. ClinicalTrials.gov: NCT05882045.
Eli Lilly and Company. “Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of type 2 diabetes.” Press release, March 2026. ClinicalTrials.gov: NCT05929079.
Doggrell SA. “Retatrutide showing promise in obesity (and type 2 diabetes).” Expert Opinion on Investigational Drugs, 32(11), 997–1001, 2023. DOI: 10.1080/13543784.2023.2283020
Kusminski CM, Perez-Tilve D, Müller TD, et al. “Transforming obesity: The advancement of multi-receptor drugs.” Cell, 187(15), 3829–3853, 2024. DOI: 10.1016/j.cell.2024.06.003
Research Disclaimer
The information provided in this article is intended for educational and research purposes only. Retatrutide (LY3437943) is an investigational compound that is not approved by the FDA or any regulatory agency for therapeutic use. This content does not constitute medical advice, diagnosis, or treatment recommendations. All peptide research compounds available through Iron Peak Peptides are sold exclusively for in vitro research, laboratory use, and scientific investigation. They are not intended for human consumption, and no claims are made regarding therapeutic efficacy or safety for use in humans. Researchers should consult applicable institutional guidelines and regulatory frameworks before conducting any research involving investigational compounds.
For research purposes only. Not for human consumption.
Related Research
→ Retatrutide vs Tirzepatide vs Semaglutide: The Ultimate GLP-1 Peptide Comparison for Researchers
→ Retatrutide: The Triple Agonist Peptide Changing Obesity Research
🔬 Explore Research Peptides
- IPP-3 RT — Price range: $89.00 through $257.00
- Ipamorelin 10mg — $52.99
- Adipotide 5mg — $69.00
- NAD+ 500mg — $69.99
